FinTechFunding

SpyGlass Ophthalmics: Closes $27.5M in Series B Financing

  • SpyGlass Ophthalmics, a Mission Viejo, CA-based ophthalmic therapeutics company, secured $27.5m in Series B financing
  • The round led by Vensana Capital with participation from existing investor New Enterprise Associates
  • In conjunction with the funding, NEA Principal Dr. Tak Cheung, formerly a board observer, will now joining the SpyGlass board
  • The company also intends to use the funds to further advance the development efforts of platform technology
  • SpyGlass Ophthalmics focused on the development of novel treatments for chronic ophthalmic diseases
  • The technology originally developed in the Sue Anschutz-Rodgers Eye Center of the University of Colorado School of Medicine and spun off-campus post-Series A funding
Previous article
Atalanta Therapeutics: Raises $110M in Series A Funding
Next article
NuProbe: Raises $42M in Funding
Steve Sam
Steve Sam
Steve Sam is a financial reporter, analyst, and commentator with a strong focus on banking technology, digital payments, and the future of financial services.

You May Also Like

FinTech

Swedish Court Delays Judgment in Klarna’s Antitrust Case Against Google

The court's decision is crucial for Klarna's operations in the competitive market.Highlights: Swedish court delays decision on Klarna's...
FinTech

Morgan Stanley Launches Bitcoin ETF, Expanding Crypto Offerings

The investment firm broadens its reach into the cryptocurrency market.Highlights: Morgan Stanley launches a Bitcoin ETF to enhance...
FinTech

HSBC Strengthens Position with Hong Kong Stablecoin Issuer License

The banking giant aims to support digital asset initiatives in the region.Highlights: HSBC receives a stablecoin issuer license...
FinTech

US Treasury Secretary Warns Banks About Anthropic’s New AI Model

Treasury Secretary highlights risks AI poses to financial stability.Highlights: US Treasury Secretary warns banks about the risks of...